News
BeiGene's Brukinsa tops Imbruvica in head-to-head contest
BeiGene is looking increasingly like it will become the leading challenger to AbbVie and Johnson & Johnson's market-leading BTK inhibitor Imbruvica for cancer, after besting its rival i
